openPR Logo
Press release

Harver Group Targets BioTech Bull

09-04-2013 12:41 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Harver Group

Synta Pharmaceuticals has a bullish outlook for Q3-Q4; insider buying indicates the company will be releasing positive research results and see a gain in returns.

Jul. 24, 2013 - CHUO-KU, Japan -- Due to the huge increase in staff and board members buying stock in Synta Pharmaceuticals, and the successful trials of Synta Pharmaceuticals latest cancer drug Ganetespib, Pharmaceutical Analysts at Harver Group are now strongly recommending the stock as a buy to investors.

Stephen James, Director of Private Equity at Harver Group in Tokyo, commented “A huge indicator for me that a stock is about to take off is insider buying. We have seen quite a bit of this over the past few weeks at Synta Pharmaceuticals, Hedge Fund Manager, Bruce Kovner who has also been on the board of directors since 2002, has bought 3 million shares for just over $13 million. President and CEO Safi Bachall also bought 10,000 shares bring his total to almost 2 million.”

Synta Pharmaceuticals (SNTA) is a biopharmaceutical corporation which creates, develops, and commercializes drugs that extend and increase the standard of living of patients with cancer and other chronic diseases. The Company has a unique library of propriety chemical compounds acquired over two decades from academic and industrial sources. These compounds are optimized through a variety of techniques to create new drug candidates.

Their most exciting new drug candidate is called Ganetespib and is used to treat lung, breast, colorectal, and hemolytic cancer. Ganetespib is a small molecular inhibitor of heat shock protein 90 (Hsp90) which is required for the maturation and activation of a number of proteins. Cancer cells thrive in the presence of Hsp90, inhibiting it can greatly reduce tumors proliferation. The drug has been tested on over 700 patients in 20 clinical trials. Although trials are not finished and the company has not released a full report, the drug has shown a lot of promise.

Nathan Marx, Head of Investment Analysis said, “Although their share price has dropped from its $10 a share high in April, I expect it to return to this price in the next three months and I am recommending my clients to buy.” Peter Anderson, Senior Vice President of Mergers and Acquisitions at Harver Group said

“This is an exciting company, on the verge of a major breakthrough, displaying all the signs of a strong financial instrument for these coming quarters, so I’m confident our clients will see growth in this area”.

Harver Group is a privately owned and run investment company with a prime focus towards world-class current projects from the early to late stages of the company’s development.

Nihonbashi Mitsui Tower, 26th Floor, 1-1, 2 Nihombashi-Muromachi
Chuo-ku, Tokyo, Japan 103-0022
Tel: +81 3 4578 1728
Fax:: +81 3 4333 7348
Email: info@harvergroup.com
Website: http://harvergroup.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Harver Group Targets BioTech Bull here

News-ID: 269634 • Views: 1498

More Releases from Harver Group

Harver Group Appoints Senior Analyst Steven Vaughan
Experienced Trader to replace Senior Analyst at Harver Group. Jul. 18, 2013 - CHUO-KU, Japan -- Today Director and Co-founder at Harver Group Koji Masuto, announced that Steven Vaughan will be taking over as Senior Analyst. Mr. Vaughan will be replacing Michael Jones, who is retiring at the end of the year after 7 years of loyal service to Harver Group. “Michael Jones has performed an indispensable role during what has
Banking Sector Roundup July 30th 2013 – A Difficult Day For A Number Of Banks
JP Morgan, Barclays, and Deutsche Bank are all having legal troubles. A JP Morgan division is accused of manipulating electricity markets, Barclays of not disclosing fees paid, and Deutsche Bank has a number of charges levied against it. Jul. 31, 2013 - CHUO-KU, Japan -- Major banks across the global are having legal and financial difficulties including; JP Morgan, Barclays, and Deutsche Bank. A division of JP Morgan Chase & Co.
European Markets Overview – 29th July 2013
Analysts at equity researcher Harver Group report advertising firms were some of the biggest gainers on Monday while Barclays and Ryan air share prices declined significantly. Jul. 30, 2013 - CHUO-KU, Japan -- The Stoxx Europe 600 index climbed half a point to 300.2, after a 0.2% dip on Friday. We expect the markets to remain fairly stagnant until later this week, as investor monitor meetings of The European Central Bank,
Lifetime Achievement Award Given to Martin Owen At Harver Group
At Harver Group´s annual awards dinner last weekend, Senior Analyst Mr. Martin Owen received the Company’s highest honor; The Lifetime Achievement Award. Jul. 11, 2013 - CHUO-KU, Japan -- "We here at Harver Group are tremendously proud of Martin Owen, he joined Harver Group at its inception 10 years ago and since then, he has continually been a beacon of integrity and hard work. He has always put the clients first

All 5 Releases


More Releases for Pharmaceutical

Metronidazole Market by Top Manufacturers – Hongyuan Pharmaceutical, Yinhe Aar …
Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc. Get Sample Copy of this Report @ https://www.bigmarketresearch.com/request-sample/2724380?utm_source=Anil&utm_medium=OPR Scope of the Report: This report focuses on the Metronidazole in global market, especially in
Metronidazole Market by Top Manufacturers – Hongyuan Pharmaceutical, Yinhe Aar …
Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc. Get Sample Copy of this Report @ https://www.bigmarketresearch.com/request-sample/2724380?utm_source=Anil&utm_medium=OPR Scope of the Report: This report focuses on the Metronidazole in global market, especially in
Metronidazole Market to 2023 (+5% CAGR Expected) Top Player Profiles – Hongyua …
Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc. Get Sample Copy of this Report @ https://www.bigmarketresearch.com/request-sample/2724380?utm_source=Anil&utm_medium=OPR Scope of the Report: This report focuses on the Metronidazole in global market, especially in
Metronidazole Market by Top Key Participant Hongyuan Pharmaceutical, Yinhe Aarti …
Metronidazole is an antibiotic and antiprotozoal medication, with the chemical formula C6H9N3O3 of can be used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis among others. Metronidazole is white crystalline powder, which can also be called as Fragyl Orvagil, Trichazol, Metronid, etc. Get Sample Copy of this Report @ https://www.researchbeam.com/global-metronidazole-2018-by-manufacturers-regions-type-and-application-forecast-to-2023-market/request-sample?utm_source=Anil Scope of the Report: This report focuses on the Metronidazole in global market, especially in North
Evolving Pharmaceutical Marketing Strategies
Publisher’s latest report,"Evolving Pharmaceutical Marketing Strategies: Digital as a Key Component of Multichannel Marketing" provides a comprehensive analysis of the changing pharmaceutical marketing landscape in the digital age. While the pharmaceutical industry readily adopts new technologies to provide medical advancements, it has been much slower to adopt technology within its marketing efforts, mostly relying on traditional channels and methods. However, the decreasing effectiveness of these traditional channels, given changing physician, patient
Vitamin C Market 2017 -CSPC Pharmaceutical Group, DSM, Shandong Luwei Pharmaceut …
Apex Research, recently published a detailed market research study focused on the "Vitamin C Market" across the global, regional and country level. The report provides 360° analysis of "Vitamin C Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Vitamin C industry, and estimates the future trend of Vitamin C market